Visugromab

Monoclonal antibody

Also known as CTL-002

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Also in development:Bladder Cancer · Phase 2

Featured evidence outside this drug's tracked markets:VINCIT (NCT07112196) · Cancer-associated Cachexia · Phase 2/3 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Other / comorbidity
NCT07112196 · CatalYm GmbH
2026-04-16 – 2030-12 · Cancer-associated Cachexia
What this study did
Phase 2 (4)
Bladder Cancer
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07219459 · CatalYm GmbH
2026-03-19 – 2031-09 · Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04725474 · CatalYm GmbH
2020-12-09 – 2030-04-30 · Solid Tumor, Adult
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Bladder Cancer: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Visugromab: this drugPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
Nogapendekin Alfa Inbakicept (Anktiva)ApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
MK-3120Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Visugromab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
Phase 1/2Solid Tumor, AdultActive not recruiting
Est. primary completion 2028-04-30 · NCT04725474 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-03-31 · NCT07098988 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma …Recruiting
Est. primary completion 2029-09 · NCT07219459 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-10-01 · NCT07246863 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2/3Cancer-associated CachexiaRecruiting
Est. primary completion 2029-12 · NCT07112196 · CT.gov ↗
What to watch

See the full readout calendar ↗